17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxy-6β-morphinan | 83514-37-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxy-6β-morphinan
• CAS: 83514-37-8
• 化学式: C₂₅H₃₀N₂O₆
• 分子量: 454.523
• InChiKey: PQKHESYTSKMWFP-GNVGSYGNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.17
• 重原子数：
  33.0
• 可旋转键数：
  5.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  108.33
• 氢给体数：
  3.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxy-6β-morphinan 在 4 A molecular sieve 、 caesium carbonate 、 三乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 504.0h， 生成 17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxy-6β-maleimidomorphinan
  参考文献：
  名称：

  具有非平衡阿片样激动剂和拮抗剂活性的纳曲酮衍生的亲和标签的设计和合成。在不同组织中存在不同mu受体亚型的证据。

  摘要：

  合成了一系列β-富纳曲胺（2，β-FNA）类似物（3-14），它们包含在鸦片剂的6β-位连接的各种亲电基团。这些配体的阿片样物质激动剂和拮抗剂活性在豚鼠回肠（GPI）和小鼠输精管（MVD）体外测定中进行了评估。几种化合物的行为类似于β-FNA，因为它们在κ阿片受体上表现出可逆的激动剂活性，而在μ阿片受体上表现出不可逆的拮抗剂活性。一系列相关迈克尔受体的不可逆拮抗作用的等级顺序与它们的内在化学反应性并不平行，这证实了共价结合的程度部分取决于亲电子中心相对于受体亲核试剂的空间位置（二次识别）。马来酰亚胺基乙酰胺8的行为与β-FNA非常不同，相对于GPI中的mu阻滞，它在MVD中表现出更大的不可逆mu拮抗作用。这表明在两个组织中存在不同比例的mu受体亚型。测试的几种药物，包括一些非反应性对照化合物，在GPI中表现出不同寻常的持久性Kappa激动剂活性。该活性通过添加纳洛酮而逆转，在洗涤时再次出现

  DOI：

  10.1021/jm00376a018
• 作为产物：
  描述：

  (5alpha,6beta)-6-氨基-17-(环丙基甲基)-4,5-环氧-吗喃-3,14-二醇 在 caesium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 10.0h， 生成 17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxy-6β-morphinan
  参考文献：
  名称：

  Importance of carbon 6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels

  摘要：

  A series of five epimeric pairs of naltrexone derivatives that contain an electrophilic substituent at the 6 alpha- or 6 beta-position was synthesized and tested on the guinea pig ileal longitudinal muscle (GPI) and mouse vas deferens (MVD) preparations in order to determine if the orientation of the electrophile is important for covalent bonding to opioid receptors. In the GPI all compounds were pharmacologically active as reversible agonists, but only the 6 beta-isomers of the fumaramate ester 2b (beta-FNA) and isothiocyanate 6b exhibited covalent reactivity, involving a selective irreversible antagonism of the mu agonist, morphine, without affecting kappa agonists. The 6 alpha-isomer 2a (alpha-FNA) was itself nonalkylating but was able to protect the GPI against alkylation by its epimer, beta-FNA, indicating that the two epimers bind to the same receptor. These results suggest that the proper orientation of the electrophilic substituent is required for covalent bonding with a proximal nucleophile in the case of mu receptor blockade. Moreover, the lack of covalent bonding to kappa receptors by these or other ligands in this series indicates the possible absence of sufficiently reactive nucleophiles on this recognition site. In the MVD, 2b, but not 2a, irreversibly antagonized morphine (as in GPI), whereas neither epimer exhibited irreversible antagonism toward the delta agonist, [D-Ala2,D-Leu5]enkephalin (DADLE). In contrast, both of the isothiocyanate epimers (6a,b) irreversibly blocked mu and delta receptors. Evidence suggesting differences between mu receptors in the MVD and GPI was obtained with the beta-iodoacetamide 5b, which was an irreversible blocker of morphine only in the MVD. When analyzed together with those of previous studies with the nitrogen mustard analogues, alpha- and beta-chlornaltrexamine, the data suggest that the receptor-alkylating ability of each isomer in an epimeric pair differs most when the electrophile possesses a narrow spectrum of reactivity.

  DOI：

  10.1021/jm00363a005